CG Oncology, Inc. (CGON) Current Ratio
- Current ratio · latest quarter: Value 22.22×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 22.22× | Current assets / current liabilities. $1.05B ÷ $47.24M ≈ 22.22× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.05B USD | Assets, Current |
| Current obligations | 47.24M USD | Liabilities, Current |
| Cash and equivalents | 19.64M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 1.01B USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | 1.00M USD | Inventory, Net |
| Payables | 12.73M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.05B | $47.24M | $19.64M | $1.01B | (m) | $1.00M | $12.73M | (m) | 22.22× |
| 2026-03-31 | $1.10B | $35.22M | $33.70M | $1.04B | (m) | $1.49M | $8.24M | (m) | 31.30× |
| 2025-12-31 | $759.48M | $30.84M | $32.49M | $709.66M | (m) | $1.56M | $5.71M | (m) | 24.63× |
| 2025-09-30 | $695.79M | $30.53M | $45.15M | $635.12M | (m) | $1.50M | $9.19M | (m) | 22.79× |
| 2025-06-30 | $673.03M | $30.38M | $14.62M | $646.43M | (m) | (m) | $7.13M | (m) | 22.15× |
| 2025-03-31 | $701.19M | $22.64M | $41.47M | $646.96M | (m) | (m) | $6.73M | (m) | 30.97× |
| 2024-12-31 | $754.21M | $21.37M | $257.07M | $484.93M | (m) | $0.00 | $6.52M | (m) | 35.30× |
| 2024-09-30 | $552.08M | $15.63M | $43.41M | $497.30M | (m) | (m) | $4.08M | (m) | 35.32× |
| 2024-06-30 | $563.86M | $11.85M | $25.16M | $527.72M | (m) | (m) | $4.49M | (m) | 47.57× |
| 2024-03-31 | $578.61M | $9.98M | $77.47M | $489.04M | (m) | (m) | $4.66M | (m) | 57.95× |
| 2023-12-31 | $194.12M | $14.25M | $8.27M | $179.41M | (m) | (m) | $3.24M | (m) | 13.62× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |